discovered that the high-affinity antibody 14D11 targeting Gal3 inhibits tumor growth in high-grade serous ovarian cancers expressing MUC16, offering a new therapeutic strategy for MUC16-positive cancers (151). Here, MUC16 is linked to neoplasm.